Management and Treatment of Recurrent Epithelial Ovarian Cancer

被引：45
作者：
Armbruster, Shannon [1 ]
Coleman, Robert L. [1 ]
Rauh-Hain, Jose Alejandro [1 ,2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1155 Herman Pressler, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hlth Serv Res, Unit 1444, 1515 Holcombe Blvd,POB 301402, Houston, TX 77230 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期
关键词：
Ovarian cancer; Recurrence; PARP; Immunotherapy; Chemotherapy; Secondary cytoreduction; PLATINUM-RESISTANT OVARIAN; PEGYLATED LIPOSOMAL DOXORUBICIN; SECONDARY CYTOREDUCTIVE SURGERY; CONTROLLED PHASE-III; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; TUMOR ANGIOGENESIS; ANTITUMOR-ACTIVITY;
D O I：
10.1016/j.hoc.2018.07.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.
引用
收藏
页码：965 / +
页数：19
相关论文
共 70 条
[31]   Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour? [J].
Kaye, Stanley B. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5150-5152
[32]   PARP inhibitors in ovarian cancer [J].
Ledermann, J. A. .
ANNALS OF ONCOLOGY, 2016, 27 :40-44
[33]   Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].
Ledermann, Jonathan ;
Harter, Philipp ;
Gourley, Charlie ;
Friedlander, Michael ;
Vergote, Ignace ;
Rustin, Gordon ;
Scott, Clare ;
Meier, Werner ;
Shapira-Frommer, Ronnie ;
Safra, Tamar ;
Matei, Daniela ;
Macpherson, Euan ;
Watkins, Claire ;
Carmichael, James ;
Matulonis, Ursula .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392
[34]   Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer [J].
Ledermann, Jonathan A. ;
Embleton, Andrew C. ;
Perren, Timothy ;
Jayson, Gordon C. ;
Rustin, Gordon J. S. ;
Kaye, Stanley B. ;
Hirte, Hal W. ;
Oza, Amit M. ;
Vaughan, Michelle Margaret ;
Friedlander, Michael ;
Martin, Antonio Gonzalez ;
Clark, Elizabeth ;
Popoola, Babasola ;
Farrelly, Laura ;
Swart, Ann Marie ;
Cook, Adrian ;
Kaplan, Richard S. ;
Parmar, Mahesh K. B. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35]   Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial [J].
Ledermann, Jonathan A. ;
Harter, Philipp ;
Gourley, Charlie ;
Friedlander, Michael ;
Vergote, Ignace ;
Rustin, Gordon ;
Scott, Clare ;
Meier, Werner ;
Shapira-Frommer, Ronnie ;
Safra, Tamar ;
Matei, Daniela ;
Fielding, Anitra ;
Spencer, Stuart ;
Rowe, Philip ;
Lowe, Elizabeth ;
Hodgson, Darren ;
Sovak, Mika A. ;
Matulonis, Ursula .
LANCET ONCOLOGY, 2016, 17 (11) :1579-1589
[36]   Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Ledermann, Jonathan A. ;
Embleton, Andrew C. ;
Raja, Fharat ;
Perren, Timothy J. ;
Jayson, Gordon C. ;
Rustin, Gordon J. S. ;
Kaye, Stan B. ;
Hirte, Hal ;
Eisenhauer, Elizabeth ;
Vaughan, Michelle ;
Friedlander, Michael ;
Gonzalez-Martin, Antonio ;
Stark, Daniel ;
Clark, Elizabeth ;
Farrelly, Laura ;
Swart, Ann Marie ;
Cook, Adrian ;
Kaplan, Richard S. ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10023) :1066-1074
[37]   Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study [J].
Liu, Joyce F. ;
Barry, William T. ;
Birrer, Michael ;
Lee, Jung-Min ;
Buckanovich, Ronald J. ;
Fleming, Gini F. ;
Rimel, B. J. ;
Buss, Mary K. ;
Nattam, Sreenivasa ;
Hurteau, Jean ;
Luo, Weixiu ;
Quy, Philippa ;
Whalen, Christin ;
Obermayer, Lisa ;
Lee, Hang ;
Winer, Eric P. ;
Kohn, Elise C. ;
Ivy, S. Percy ;
Matulonis, Ursula A. .
LANCET ONCOLOGY, 2014, 15 (11) :1207-1214
[38]   A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer [J].
Liu, Joyce F. ;
Tolaney, Sara M. ;
Birrer, Michael ;
Fleming, Gini F. ;
Buss, Mary K. ;
Dahlberg, Suzanne E. ;
Lee, Hang ;
Whalen, Christin ;
Tyburski, Karin ;
Winer, Eric ;
Ivy, Percy ;
Matulonis, Ursula A. .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) :2972-2978
[39]   Targeted therapy for cancer using PARP inhibitors [J].
Lord, Christopher J. ;
Ashworth, Alan .
CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) :363-369
[40]   Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design [J].
Markman, M ;
Markman, J ;
Webster, K ;
Zanotti, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3120-3125
1234567